Calidi Biotherapeutics plans $1.2M registered direct offering

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) has entered into a definitive stock purchase agreement with accredited investors and qualified institutional buyers for a registered direct offering of 1,025,640 shares of common stock at $1.17 per share.

The gross proceeds from the offering are expected to be approximately $1.2 million before deducting offering expenses. The company said it intends to use the net proceeds for working capital and general corporate purposes.

The closing of the offering is expected to occur on or about September 18, 2026, subject to customary closing conditions.

The securities are being offered under a shelf registration statement on Form S-3, declared effective by the U.S. Securities and Exchange Commission on October 10, 2024.

You May Also Be Interested In

• Atossa Therapeutics sets CVR plan tied to potential FDA voucher
• Evolution Metals raises fiscal 2026 revenue guidance by 62% at midpoint
• Scotiabank Upgrades Webull (BULL) to Sector Outperform